Heparin Neutralization of PGI 2 : Effects Upon Platelets
Hussain I. Saba, Sabiha R. Saba, C Blackburn, Robert C. Hartmann, Reginald G. Mason
Abstract
Hussain I. Saba, Sabiha R. Saba, C Blackburn, Robert C. Hartmann, Reginald G. Mason
Abstract
Heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on platelet aggregation. The PGI2-induced enhancement of platelet cyclic adenosine monophosphate levels is also inhibited. The mechanism appears to involve a direct interaction in which heparin neutralizes the inhibitory effects of PGI2 on platelet aggregation but, at the same time, does not lose its own anticoagulant activity. These findings may explain instances in which heparin infusions have been reported to produce hyperaggregation of platelets, thrombotic episodes, and thrombocytopenia in patients.
OpenAlex reports 68 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on platelet aggregation. The PGI2-induced enhancement of platelet cyclic adenosine monophosphate levels is also inhibited. The mechanism appears to involve a direct interaction in which heparin neutralizes the inhibitory effects of PGI2 on platelet aggregation but, at the same time, does not lose its own anticoagulant activity. These findings may explain instances in which heparin infusions have been reported to produce hyperaggregation of platelets, thrombotic episodes, and thrombocytopenia in patients.
Key concepts: Prostacyclin, Heparin, Platelet, Chemistry, Inhibitory postsynaptic potential, Anticoagulant, Adenosine diphosphate, Pharmacology